These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18416588)

  • 1. Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.
    Frampton JE; Wagstaff AJ
    Drugs; 2008; 68(6):839-53. PubMed ID: 18416588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.
    Konigs C; von Hentig N
    Drugs Today (Barc); 2009 Jul; 45(7):549-61. PubMed ID: 19834631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.
    Delumeau JC; Ikegawa C; Yokoyama C; Haupt V
    Thromb Haemost; 2008 Jul; 100(1):32-7. PubMed ID: 18612535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octocog alfa (Advate®): a guide to its use in hemophilia A.
    Keating GM; Dhillon S
    BioDrugs; 2012 Aug; 26(4):269-73. PubMed ID: 22759264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.
    Kenet G; Moulton T; Wicklund BM; Ahuja SP; Escobar M; Mahlangu J
    J Blood Med; 2023; 14():379-388. PubMed ID: 37309365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
    Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
    Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
    Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.
    Rothschild C; Scharrer I; Brackmann HH; Stieltjes N; Vicariot M; Torchet MF; Effenberger W
    Haemophilia; 2002 Mar; 8 Suppl 2():10-4. PubMed ID: 11966846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J; Zhao Y; Wu J; Sun J; Wang L; Yang R
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Tueckmantel C; Cabre-Marquez JF; Wang M
    Eur J Haematol; 2023 Jan; 110(1):77-87. PubMed ID: 36192847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W; Gill JC; Rothschild C; Manco-Johnson MJ; Lusher JM; Kellermann E; Gorina E; Larson PJ;
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octocog alfa, plasma/albumin-free method.
    McCormack PL; Plosker GL
    Drugs; 2005; 65(18):2613-20, discussion 21-2. PubMed ID: 16392876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.